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Abstract: The European Institute for Innovation through Health Data (i~HD) has been formed as one of the sustainable 
entities arising from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects, 
in collaboration with other European Commission projects and initiatives. The vision of i~HD is to become the    
European organisation of reference for guiding and catalysing the best, most efficient and trustworthy uses of health 
data and interoperability, for optimizing health and knowledge discovery. i~HD has been established in recognition that 
there is a need to tackle areas of challenge in the successful scaling up of innovations that rely on high-quality and in-
teroperable health data, to sustain and propagate the results of eHealth research, and to address current-day obstacles to 
using health data. i~HD was launched at an inaugural conference in Paris, in March 2016. This was attended by over 
200 European clinicians, healthcare providers and researchers, representatives of the pharma industry, patient associa-
tions, health professional associations, the health ICT industry and standards bodies. The event showcased issues and 
approaches, that are presented in this paper to highlight the activities that i~HD intends to pursue as enablers of the bet-
ter uses of health data, for care and research. 
Keywords: electronic health records; clinical research; real world data; information governance; interoperability stand-
ards; quality assurance 
 
*Correspondence to: Dipak Kalra, Department Medical Informatics & Statistics, Building 3, 5th Floor, Ghent University Hospital, De 
Pintelaan 185, Gent 9000, Belgium; Email: dipak.kalra@i-hd.eu 
Received: December 7, 2016; Accepted: December 29, 2016 
Citation: Kalra D, Sundgren M, Claerhout B, et al. 2017, The launch of the European Institute for innovation through health data. 
Journal of Medicines Development Sciences, 3(1): 165. http://dx.doi.org/10.18063/jmds.v3i1.165. 
The launch of the European Institute for innovation through health data 
 
2 Journal of Medicines Development Sciences (2017)–Volume 3, Issue 1 
 
1. Introduction 
s electronic health record (EHR) systems pro-
liferate across large and small healthcare or-
ganisations, such as hospitals and general 
practices, and providers migrate from paper to elec-
tronic systems for routine clinical documentation, 
there is an increasing wealth of fine-grained health 
data that can support better quality patient care, health 
system decision-making and clinical research. For 
example, 96% of US hospitals now have EHR systems 
that meet the requirements of the Office of the Na-
tional Coordinator for Health Information Technology 
(ONC)
[1]
. Over 90% of general practitioners in the 
United Kingdom, Netherlands, Australia, and New 
Zealand use EHR systems
[2]
.  
This fine-grained health data is progressively be-
coming more and more structured and coded, rather 
than free text (word processed) letters and reports. 
This increases the computability of the data, enabling 
the greater application of smart analytics such as deci-
sion support, reminder and alerting systems, care path-
way management systems and querying populations 
of EHRs for public health, academic and industry re-
search and safety monitoring such as pharmacovigi-
lance
[3]
.  
Health care systems need to demonstrate that they 
are cost-effective, are working towards optimising 
clinical outcomes and patient satisfaction, and are 
proactive in the monitoring and prevention of patient 
safety issues including those due to poor care coordi-
nation and communication
[4]
. To illustrate the patient 
safety challenge, the US Food and Drug Administra-
tion (FDA) estimate that medication errors cause 
around one death every day and injure 1.3 million 
people annually in the United States
[5]
. 
Unmet medical needs, chronic diseases, ageing 
populations, and the emergence of personalised medi-
cine are amongst the factors contributing to a growing 
consumer demand for the highest quality of healthcare 
and accelerated research into effective and safe inno-
vative medicines.  
However, pharmaceutical innovation faces numer-
ous R&D challenges causing significant study delays 
and increased costs. Over the last 12 years, the aver-
age cost of conducting clinical trials has increased 
three-fold. The number of drug development programs 
has grown by an average of 6% per year from 2002 to 
2011. In parallel, clinical research is growing in com-
plexity and labour intensity. This is partly due to the 
need to conduct large clinical trials that provide defin-
itive evidence of clinical benefits and safety, and to 
the increasing demand from regulators and payers to 
generate value-based evidence which requires con-
ducting further studies to assess the ―real-word‖ com-
parative effectiveness, safety and cost-effectiveness of 
innovative medicines compared to existing therapies. 
The pharma industry is under increasing pressure to 
contain the growing costs of conducting clinical trials 
whilst in parallel generating more and more evidence, 
and to reduce the delays in conducting those trials, 
which are largely due to challenges in patient recruit-
ment
[6]
. The main bottlenecks in current clinical re-
search include sub-optimal protocol designs, slow and 
lengthy patient recruitment, and labour-intensive and 
time-consuming clinical study conduct. Specific is-
sues include the difficulty in evaluating patient popu-
lations and in optimising protocol design, identifying 
suitable patients for clinical trials, the manual and re-
dundant re-entry of data, the reliability of data sources, 
and the difficulty in detecting and reporting infrequent 
adverse events.  
Evidence is now emerging of practical and trust-
worthy ways in which EHRs can be reused for re-
search in order to optimise clinical trial protocols, 
identify the sites most likely to recruit sufficient pa-
tient numbers, and to assist those sites with tracking 
the patients who meet trial eligibility criteria
[7]
. There 
is now also growing evidence that the reuse of EHRs 
in this way is cost-beneficial to the pharma industry
[8]
. 
There are growing opportunities for using health 
data to engage patients more directly in their own ill-
ness self-management and in the collection of data 
during clinical trials. Innovations such as wearable 
sensors, smartphone applications, lab on a chip com-
bined with the ubiquity of video communications ena-
ble remote clinical consultations, the tracking of 
physiological parameters and feedback systems to 
patients to be delivered at a low cost and in ways that 
are well accepted by patients
[9]
. 
Perhaps the most exciting opportunity, attracting 
multi-million investments from European and US 
governments and from pharma, is the potential for 
conducting research directly on large population data 
sets derived from routinely collected clinical data, 
known as ―Real World Data‖ and sometimes as ―big 
health data‖. Apart from traditional epidemiological 
research, analyses of large population data repositories 
has the potential to generate evidence for comparative 
effectiveness studies, biomarker validation, fine-gra-
A 
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ined stratification of patients for risks and to optimise 
treatment outcomes
[10]
.  
However, much as there is excitement about the 
opportunities from scaling up the use of health data, in 
particular for research, there are concerns about 
providing confidence to the public that such uses of 
their data can be undertaken in ways that protect their 
privacy and respect the confidentiality of the disclo-
sures they have made to health professionals
[11]
.   
A second challenge lies in the integration of the da-
ta themselves, which originate in multiple electronic 
health record systems that have different information 
structures, use different terminology systems and are, 
of course, often captured in different natural languages. 
There are interoperability standards published by sev-
eral international Standards Development Organisa-
tions (SDOs) that can help address this heterogenei-
ty, by providing harmonised representations that 
can be used to communicate data or used to construct 
a consolidated data repository for analysis. However, 
uptake of the standards by the vendors of EHR sys-
tems is proving slow, due to weak market incentives, 
and interoperability between these systems remains 
piecemeal and limited. 
2. The European Institute for Innovation 
through Health Data 
The challenges of privacy protection and interopera-
bility are being addressed through many different re-
search and development initiatives, such as those 
sponsored by the European Commission through its 
Framework Programmes and Horizon 2020, and al-
so by many national and regional eHealth programmes. 
However, these solutions themselves often remain in 
silos, are not propagated or maintained, and therefore 
fail to combine and scale up to deliver holistic solu-
tions to these problems. In order to address this, at a 
European level, and arising from some such European 
projects, a new not for profit European Institute was 
launched in 2016: the European Institute for Innova-
tion through Health Data (i~HD). This institute was 
created in order to unite efforts to enable better uses of 
health data for the benefit of learning health systems 
and clinical research
[12]
: 
 To play a central role in governing and ex-
panding a trustworthy health data driven eco-
system including EHRs and clinical research 
platforms; 
 To promote the adoption of healthcare standards 
and of data quality, to enable more effective, 
safer and better integrated healthcare; 
 To act as a connector between health care and 
clinical research standards, that are presently 
developed in silos and impair the interopera-
bility and pooling of health data for research; 
 To promote to society the importance of using 
health data for research, to improve efficiency 
through reduced duplications, delays, costs 
enhance speed and efficiency in clinical stud-
ies. 
i~HD held its inaugural conference and public 
launch in March 2016, in Paris. The inaugural confer-
ence brought together over 200 experts from across 
Europe, including health ministries, insurers, the 
pharma industry, healthcare providers, patient associa-
tions, health professional associations, the health ICT 
industry and standards bodies. The rest of this paper 
summarises the key initiatives and themes that were 
presented during that conference, and which indicate 
the priorities that i~HD will address in the coming years. 
3. Re-using health data for research: outcomes 
of the EHR4CR Project 
The EHR4CR project (2011–2016) with a budget of 
+16 million Euro, involved 35 academic and private 
partners (10 pharmaceutical companies) and was one 
of the largest of the IMI Public-Private Partnerships in 
this area (Figure 1). The consortium included 11 hos-
pital sites in France, Germany, Poland, Switzerland 
and the United Kingdom. It was part-sponsored by the 
European Commission through the Innovative Medi-
cines Initiative (IMI). 
 
 
 
Figure 1. The overall objective of EHR4CR 
 
The coordinator of EHR4CR, Mats Sundgren from 
AstraZenca, explained to the conference that the pro-
ject has developed a robust and scalable platform that 
can utilise de-identified data from hospital EHR sys-
tems, in full compliance with the ethical, regulatory 
and data protection policies and requirements of each 
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participating country
[13]
. The EHR4CR platform sup-
ports distributed querying to assist in clinical trials 
feasibility assessment and patient recruitment. The 
platform can connect securely to the data within mul-
tiple hospital EHR systems and clinical data ware-
houses across Europe, to enable a trial sponsor to pre-
dict the number of eligible patients for a candidate 
clinical trial protocol, to assess its feasibility and to 
locate the most relevant hospital sites. Applications 
are offered to connected hospitals to assist them to 
efficiently identify and contact the patients who may 
be eligible for particular clinical trials. The EHR4CR 
solution is compliant with EU legislation and respects 
the position of hospital and patients towards their 
health data. Patient level data never leaves the con-
nected hospitals.  
This development has required securing acceptance 
from the patients, the public and the research and 
health service communities. Therefore, in parallel to 
the technical developments, senior level decision 
makers, ethics boards and industry executives and 
scientists, were consulted to provide strategic insights 
into the most robust and acceptable technical and pro-
cedural approaches that should be taken to ensure pri-
vacy protection and compliance with European and 
national/regional regulations on data protection.  
EHR4CR has shown that such a platform has the 
potential to significantly improve the efficiency of 
designing and conducting clinical trials, reducing time 
and costs, reducing administrative burdens, optimising 
protocol feasibility assessments, accelerating patient 
recruitment, making study conduct more efficient, 
enabling the participation of European hospitals in the 
more clinical trials and thereby potentially increasing 
research income
[14]
. 
The European Institute for Innovation through 
Health Data arose in part out of the EHR4CR project, 
to develop and promote best practices in the govern-
ance, quality, semantic interoperability and uses of 
health data, including its reuse for research. An im-
portant role of i~HD is to provide independent gov-
ernance oversight of clinical research platforms and 
their expanding networks of hospitals. 
The first EHR4CR service provider, Custodix
[15]
 is 
now launching its operational platform, InSite
[16]
, for 
Europe-wide deployment, to be governed by i~HD.  
An early adopter Champion Programme (CP) has 
been launched as a first step in building a pan-Eur-
opean network of hospitals connected to the InSite 
Platform. The objectives are to start building a com-
munity of hospitals interested in reusing their EHR 
data for research, to further validate and improve the 
technology and to refine the business model, creating 
a win for all stakeholders. It is designed to provide a 
low-risk entry for all stakeholders into a new business 
model approach to efficient use of Real World Data. 
Thus, the programme is a key step in building the 
EHR4CR envisaged ecosystem of network of hospi-
tals, service providers and pharma users. The CP aims 
at proving the value of Real World Data for clinical 
research and the InSite technology on a wide scale. 
Brecht Claerhout, the CEO of Custodix, explained 
that in 2015 the industry partners, Custodix and i~HD 
developed a collaboration model that outlined princi-
ples, terms and budgets for the CP. The eight involved 
industry partners, a.k.a. Industry Champions, are 
Amgen, AstraZeneca, GlaxoSmithKline, Janssen, 
Roche, Sanofi (as previous EHR4CR Efpia partners), 
ICON plc, and Boehringer-Ingelheim. Each industry 
partner sponsors the connection/setup of three hospi-
tals of preference to the InSite platform. Each spon-
soring Industry Champion selects these Champion 
Hospitals, in full transparency with the other Industry 
Champions. The programme will also involve gov-
ernance through the i~HD Institute. The budget model 
for industry partners includes for each Industry 
Champion to provide in-kind support at various stages 
of the CP (e.g. to provide the necessary resources to 
propose validation plans and support their execution) 
and a fee to become members of the i~HD Institute. 
The scope of the CP is to have a 15 – 30 Champion 
Hospitals from different EU countries, giving access 
to at least 2 million patients. The programme aims at 
including at least one US hospital to demonstrate the 
global ambition of the program. The current candidate 
Champion Hospitals include organisations from Swe-
den, UK, Poland, Netherlands, Germany, Spain, Fran-
ce, Belgium, Finland, Switzerland and Italy.   
The first phase of the CP, through to 2017, will of-
fer opportunities for industry partners to execute the 
EHR4CR Protocol Feasibility Service, and Patient 
Identification & Recruitment service across all hospi-
tals connected to the platform, for on-going trials. It 
will provide business value to participating industry 
and to hospitals. Industry partners will have access to 
a new innovative tool for better trial design by opti-
mising clinical protocols through direct responses 
from updated EHR data. The protocol feasibility test-
ing service will allow fast iterations of inclusion/ex-
clusion criteria, which will reduce costly corrective 
measures such as protocol amendments, late addition 
of new trial countries or sites. The established, and 
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growing, hospital network in place will improve trial 
success rates and reduce the number of trials failed 
due to failure to recruit. Champion hospitals will be 
able to attract more clinical research studies and use 
the InSite tools to speed up identification of trial can-
didates and enable in house research and other learn-
ing health system analyses. 
Through the sponsoring process and transparency 
within the industry Champion group, Industry Cham-
pions will be able to improve their relationship with a 
growing network of hospitals. The pre-competitive 
collaboration model brings benefits in allowing indus-
try to jointly validate and improve the InSite platform 
while working with i~HD in refining the rules of en-
gagement for a sustainable ecosystem. Furthermore, 
this jointly-undertaken initiative removes the need for 
each individual company to establish their own hospi-
tal network. 
The intention is to secure a long term relationship 
with all actors and to further expand this novel eco-
system for supporting clinical research using EHRs in 
Europe and beyond. The ambition is to grow the net-
work by attracting more hospital sites to join the plat-
form, involve more service providers, and more end- 
users from both industry and academic centres. 
4. Scaling up the use of big health data 
The Executive Director of the Innovative Medicines 
Initiative (IMI) Pierre Meulien, told the audience that 
IMI is investing over 5 billion Euros in public private 
research projects
[17]
. He emphasised its ambition of 
improving the affordability and speed of access to 
innovations for patients. The first IMI programme 
funded 59 projects with a budget of €2 billion. IMI2, 
recently launched, has a budget of €3.3 billion, with a 
more ambitious scope. Many of these IMI projects are 
using electronic health records to speed up clinical 
trials and using big data to discover how to better tar-
get innovative therapies to the particular patients who 
will respond best to them. The new Big Data for Bet-
ter Outcomes programme, part of IMI2, will also work 
closely with health care stakeholders to help apply 
new evidence emerging from big data to improve 
healthcare systems (Figure 2).  
Participants also learned about Europe s´ largest 
―big data‖ project in health: the European Medical 
Information Framework (EMIF, funded by IMI) from 
its co-ordinator Bart Vannieuwenhuyse, of Janssen. 
EMIF is creating an environment that allows for the 
efficient re-use of existing health data (the EMIF 
Platform). To ensure immediate applicability, EMIF 
includes two specific research topics that are helping 
to guide the development of the Platform: the identi-
fication and validation of protective and precipitating 
factors for conversion to Alzheimer‘s Disease (EMIF- 
AD) and predictors of metabolic complications of 
obesity (EMIF-Metabolic). 
The EMIF Platform‘s primary objective is to facili-
tate the re-use of healthcare data. Given the variety of 
data sources that may be useful for research, it will 
enable identification, assessment and selection of su-
itable data sources (the EMIF data catalogue, Figure 3).  
 
 
Figure 2. The vision for the IMI2 programme 
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Figure 3. The EMIF Catalogue of research data sources 
 
Because data come from multiple sources and have 
different formats and content, the Platform harmonises 
the data according to well established data format and 
semantic standards to enable answering the research 
questions. Under a global philosophy of creating data 
platforms (federation), connecting software (data ex-
traction software) and mechanisms for governance 
(legal, ethical and privacy) are also included in the 
work plan. Platform development, including data ac-
cess, analysis and visualisation is addressed using an 
agile paradigm in which user requirements gathering 
and prototype evaluation are iteratively undertaken.  
EMIF-AD and EMIF-Metabolic serve as use sce-
narios and test beds for the Platform. EMIF-AD aims 
to discover and validate diagnostic markers, prognos-
tic markers and risk factors for AD in non-demented 
subjects. EMIF-Metabolic aims to identify risk mark-
ers for metabolic complications of obesity, by identi-
fying and testing biomarkers in small and medi-
um-sized cohorts followed by testing in large clinical 
populations with outcome data.  
Possible sustainability models for EMIF are being 
studied in order to ensure adequate post-project con-
tinuation of products and services developed. 
5. The trustworthy reuse of health data for research 
As mentioned earlier, it is vital that the reuse of health 
data for research is considered trustworthy by society. 
This naturally means demonstrating compliance with 
data protection legislation, at a European level and 
across all European Member States. The new General 
Data Protection Regulation, replacing the existing 
European Directive, will place greater obligations on 
research users and data custodians to have undertaken 
privacy impact assessments and to have incorporated 
privacy protection as a fundamental design feature of 
systems and repositories. However, some Member 
State variation will remain in the precise rules sur-
rounding, for example, the protection of pseudony-
mised data. Nevertheless, it will be important for the 
research community to win public trust by working 
towards consistent information governance practices 
and expectations across Europe. This includes socie-
tally acceptable codes of good practice for governing 
the many uses of health data, which reflect state of the 
art in privacy protection and information security. 
These are necessary to give confidence and reduce the 
risk for those providing data for research use e.g. hos-
pitals, GPs, patients, and offer greater confidence and 
reduced risk for those performing the research, man-
aging the data or sponsoring the research. 
i~HD is working to provide several layers of guid-
ance and voluntary codes to support a consistent and 
trustworthy approach across Europe, including: 
 Quality labelling criteria for clinical research 
platforms and services; 
 Codes of Practice for feasibility studies and 
for remote data access and sharing; 
Dipak Kalra, Mats Sundgren, Brecht Claerhout, et al. 
 
 Journal of Medicines Development Sciences (2017)–Volume 3, Issue 1 7 
 Standard Operating Rules, that specify re-
quirements for technical safeguards and spec-
ified duties; 
 Standard Operating Procedures including acc-
ess controls, incident management, audit & 
monitoring; 
 A staff competence checklist and training re-
sources about data management and privacy 
protection when using research platforms; 
 The formation of an i~HD Information Gov-
ernance Board, providing voluntary oversight. 
The information governance framework (Figure 4), 
building on work led in EHR4CR by Peter Singleton, 
has been developed as an integrated design of IT con-
trols supported by organisational measures. It is linked 
with existing codes of practice, such as the IMI Code 
of Practice on the Secondary Use of Medical Data
[18]
. 
Peter explained to the conference that privacy pro-
tection is delivered on multiple levels through specific 
‗privacy by design‘ requirements: personal data is on-
ly processed by original data controller; the Clinical 
Data Warehouse holds only pseudonymised data; the 
InSite Platform only handles aggregate data, with ad-
ditional protections for small-cell data; role-based ac-
cess controls are implemented to limit access to ag-
gregate data. These controls are supported by exten-
sive audit trails with facilities for pro-active reporting, 
and are linked with organisational controls (e.g. Oper-
ating Procedures) to ensure that there is overall effec-
tiveness of the oversight of data use across the system. 
The EHR4CR Core Principles, now being taken 
forward by i~HD, are (in brief): 
 Data minimisation 
 Data exchange proto-
cols 
 Strong information se- 
curity 
 Risk management co-
ntrols 
 Appropriate access 
control facilities 
 Adequate audit trails 
 Ensure appropriate use 
 Operational effective-
ness  
 Effective information 
governance 
 Proper training & re- 
sourcing 
 Clarity of authority 
 Effective enforcement 
 Legal conformance 
The main objectives for these principles are: to build 
on legal requirements; to act as a basis for building 
and establishing trust between partners: to provide 
solid, though flexible foundations for initial operations; 
to articulate the level of controls to data providers, 
regulators, patients, and the public at large; to guide 
further development of standard operating rules and 
procedures; and to provide a possible governance 
framework for other EU healthcare projects in the fu-
ture. 
6. The importance of quality in EHR systems 
John O‘Brien told the conference that reliance of heal-
thcare delivery organisations on well governed and  
 
 
 
Figure 4. Overview of the i~HD information governance framework 
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quality assured data and information has grown pro-
gressively in recent decades and continues to at an 
ever accelerating rate. At corporate level, data and 
information are moving from a position of being 
viewed as a facilitator to one in which it holds core 
factor of hospital production status. It is increasingly 
employed as an embedded input in the diagnosis, 
treatment and care production process. Excellent and 
successful healthcare delivery has become inherently 
dependent on reliable data and information. There is a 
strong emerging example-supported view that where 
healthcare organisations employ advanced data and 
information as integrated inputs in the service produc-
tion process, they enjoy improved patient access, care 
quality and satisfaction, resource utilisation and effi-
ciency, workforce engagement and functioning and 
competitive advantage.   
As its importance and emergent factor status ad-
vances, data and information present a number of 
challenges at corporate level. These centre primarily 
around continuity assuring its quality and fully ex-
ploiting its ever expanding potential. Focus here has 
tended to concentrate on EHR‘s (in their extended 
patient pathway/multi device/multi use manifestations) 
and the information workforce.  
Other primary health service production factors 
such as facilities, devices, pharma and health care 
professionals are governed and operate within a robust 
assurance environment (e.g. regulatory/professional bod-
ies, standards based certification, mandatory creden-
tialing etc.). EHRs and the information workforce are 
not similarly governed or assured, notwithstanding 
their apparent co-input status. Related approaches 
with respect to EHRs are found mainly in certification 
and quality labelling initiatives most recently exer-
cised through application of EuroRec (EU) and ONC 
(US) standards to EHRs or elements thereof, culmi-
nating in awarding of compliance seals/certification to 
product suppliers. Information workforce credential-
ing has become a central work stream in proceedings 
of the EU/US Cooperation Forum on eHealth. Pro-
gress in both instances has however been slow and 
delivered limited success – a notable exception being 
the Belgium experience in EHR certification.  
Going forward there is a need to revisit the data and 
information governance and quality assurance agenda 
and render it much more directed and demanding. In 
the case of EHRs, the historic focus has centred on the 
supplier community. Recent endeavours to coalesce 
suppliers, funders and users (Healthcare Delivery Or-
ganisations) in the context of the eHealth eco-system 
in this respect are necessary and important develop-
ments. It is posited, however, that for long run success, 
the user community requires to be the prime focus and 
to assume lead driver status in this realm within the 
eco-system framework. Users are the prime benefi-
ciaries of essential and well governed and quality as-
sured data and information. This suggests that, at core, 
there is a concomitant onus on them to demand and 
drive related status and standards.  
User approaches in this respect might include:  
 Use of quality labelling standards to assess 
and where indicated inform adaption of in-
stallations;  
 Use of quality labelling standards as part of 
procurement specification and evaluation sys-
tems; 
 Promotion of development of dedicated data 
and information education and training pro-
grammes – particularly with affiliated Aca-
demic Institutions; 
 Advocacy and support for creation of appro-
priate professional bodies for data and infor-
mation workforce; 
 Increased location of trained/qualified data 
and information personnel in key clinical 
teams/divisions. 
There is also a compelling case for Health System 
Accreditation bodies to significantly develop their 
established standards and criteria sets with respect to 
EHR systems and the information workforce. In the 
circumstances, it is becoming evident that healthcare 
delivery organisations need to re-imagine data and 
information and its consequential governance and 
quality assurance requirements.  
7. EHR system quality labelling and certification 
Pascal Coorevits gave a presentation about EuroRec‘s 
approach to quality labelling and certification. The 
European Institute for Health Records (EuroRec, 
http://www.eurorec.org) holds the largest collection of 
quality criteria for EHRs in Europe. The EuroRec re-
pository contains more than 1700 validated functional 
quality criteria for EHR systems. This repository is 
categorised and indexed, and many of the criteria 
have been translated in 19 European languages. In 
addition to the repository, a number of tools and 
methodologies have been developed for using these 
criteria for quality labelling and certification of EHRs. 
The current collection of tools (web-based applica-
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tions) consists of (1) Composer (for browsing, select-
ing etc. the criteria from the repository), (2) Certifier 
(for creating certification ―sets‖ of selected criteria), 
(3) Scripter (tool for developing test scripts and test 
scenarios) and (4) Testing tool (for conducting, re-
porting and coordinating conformance evaluations) 
(see Figure 5).  
 
 
Figure 5. EuroRec‘s Quality Labelling and Certification Tools 
 
EuroRec‘s current portfolio of quality labelling and 
certification services is addressing quality criteria and 
functionalities of EHRs in care and research settings 
(re-use of EHR data). A formal collaboration between 
EuroRec and i~HD will be initiated regarding the 
quality labelling and certification of service providers. 
Based on international standards and experience 
through European research projects (EHR Q-TN, 
HITCH, ANTILOPE), i~HD will play the role of the 
certification body and EuroRec will be the conformity 
assessment body in this new quality assurance fra-
mework (see Figure 6). 
 
 
Figure 6. Actors involved in Quality Labelling and Certification 
 
The European Institute for Innovation through 
Health Data is currently developing a quality labelling 
and certification program for certification of health 
research platforms, services and tools. It will develop, 
together with EuroRec, the quality criteria, test plans 
and certification processes for research platforms, ser-
vices and tools which support the re-use of EHR data 
for clinical research (cf. secondary use of EHRs) to 
certify conformance to the EHR4CR specifications. In 
order to develop the quality criteria, specific interna-
tional relevant standards will be investigated, best 
practices and criteria will be investigated from rele-
vant European research projects (non-exhaustive list 
of relevant FP7, H2020 and IMI projects: EHR4CR, 
EMIF, EURECA, TRANSFORM, INTEGRATE, etc.) 
and criteria and processes from similar and comple-
mentary initiatives will be investigated (e.g. eClinical 
Forum, ECRIN criteria for clinical trial centres). A 
first set of candidate criteria will be presented to and 
discussed within an expert group. Using an iterative 
process for feedback gathering and by using a formal 
consensus method the final criteria will be developed. 
Together with the final criteria, the test methodology 
will be finalised and the governance framework 
will be installed. It is aimed that the i~HD quality la-
belling and certification program and services will be 
launched beginning of Q4 of 2016. 
8. High quality interoperable health data for 
care and research 
Collection, storage and analysis of health data has 
been, is and will be one of the fundamentals to pro-
vide efficient healthcare services and its importance is 
only increasing considering the growing amount of 
health data collected every day. The situation gets 
even more complicated because relevant health infor-
mation does not only come from traditional interviews 
and medical tests in a hospital or outpatient clinic, but 
it involves data that patients collect themselves using 
wearables for tele-monitoring and data that healthy 
people collect using wide variety of health and well-
being apps. In addition, information from other  
sources such as social platforms or data collected for a 
non-medical purpose may provide useful insights for 
better public health policy making. This rather wide 
variety of data sources is considered in the work of the 
European Commission in supporting development and 
implementation of eHealth in the EU.  
Terje Peetso
1
 told the audience that the European 
Commission has already put in place several activities 
to improve EU interoperability in healthcare
[19]
. First 
of all, eHealth interoperability is one of the 16 key 
actions under three pillars of the Digital Single Market 
Strategy
[20] 
and it is also part of the ―EU eGovernment 
Action Plan 2016-2020 - Accelerating the digital 
                                                         
1 This section expresses the personal views of the author and in no way 
constitutes a formal/official position of the European Commission. 
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transformation of government‖
[21]
 that supports Me-
mber States in the development of eHealth services 
that also enable cross-border exchange of patient data 
and e-prescriptions, based on the guidelines adopted 
by the eHealth Network
[22,23]
.  
Interoperability has a prominent role in the eHealth 
Action Plan 2012 – 2020
[24]
 in which one of the four 
areas of actions is dedicated to addressing technical, 
semantic, legal and organisational issues. As a result, 
the Commission, with the endorsement of the eHealth 
Network, proposed the Refined Health Interoperability 
Framework
[25]
 based on the results of studies, pilots 
and research projects. In addition, on 28 July 2015 the 
Commission has adopted the Decision on the identifi-
cation of ‗Integrating the Healthcare Enterprise‘ pro-
files for referencing in public procurement
[26]
.  
Furthermore, in other three areas of the Action Plan – 
―Research and Innovation‖, ―Deployment and uptake‖ 
and ―International cooperation‖ – interoperability is 
addressed directly or indirectly. For example, during 
the period 2012–2020 research and innovation fund-
ing is foreseen from the EU Framework Programme 
for Research and Innovation Horizon 2020
[27]
. Indirect 
effect on achieving interoperability is also expected 
through increasing awareness of the benefits of eHe-
alth in general as well as from better understanding of 
the importance of data sharing and cross-border coop-
eration to achieve better health outcomes. Finally, in-
teroperability is one of the three areas of the Memo-
randum of Understanding signed by the representa-
tives of the EU and US in 2010
 [28]
.  
It is important to underline that in addition to the 
activities listed above, interoperability is closely 
linked to many other documents such as the Directive 
2011/24/EU on the application of patients‘ rights in 
cross-border healthcare
[29]
, the EU Regulation 910/2014 
on electronic identification and trust services for elec-
tronic transactions in the internal market
[30]
 and the 
political agreement on the Network and Information 
Security (NIS) directive
[31]
. It is also related to actions 
following the public consultation on the Green Paper 
on mHealth
[32]
.  
A mix of actions, methods and tools support the 
process towards interoperability through engagement, 
education, development, testing, deployment, moni-
toring, knowledge sharing and feedback. All these 
activities enable healthcare providers to reach the crit-
ical mass of empowered users and break the existing 
silos which together will effectively contribute to ac-
cessing personalised medicine. 
9. Expert panel on semantic interoperability 
Following the talk by Terje, Veli Stroetmann led an 
expert panel discussion on the challenges of improv-
ing semantic interoperability across EHR systems, at a 
European level. The panel brought together the per-
spectives of health ministries (Michèle Thonnet, Jer-
emy Thorp), a clinician (Robert Vander Stichele), a 
patient (Petra Wilson) and a health insurer (Christoph 
Rupprecht), and focused on the role decision makers 
should play in promoting and supporting better learn-
ing from health data.  
In interoperable and connected systems, data can be 
used and reused across diverse settings to counter 
health system fragmentation; in cross-border situa-
tions coping with increasing mobility across Europe 
and in mobile tools to facilitate home care and self- 
management of chronic disease. Interoperability of 
eHealth solutions is essential for achieving continuity 
of care, which is the key to reducing patient risks, 
avoiding duplication and saving healthcare resources. 
Interoperability enables not just sharing of infor-
mation, it reduces clinician as well as patient burden 
to repeatedly provide data and supports the efficient 
coordination of multidisciplinary teams to provide 
seamless, integrated care. From a patient's perspective, 
the main benefit of interoperability is an end to giving 
the same information over and over again.  
The consistency and comparability of data brings 
data use a step forward from improving patient care to 
facilitating public health management and clinical 
research. All these factors are crucial to achieve a 
preventive, predictive, personalized, people-centred 
and participative health system. 
To successfully implement interoperability and to 
achieve these goals, we still have to overcome many 
challenges. Data governance and access conditions 
have to be carefully planned to provide trust to pa-
tients; and the benefits of internal secondary use of 
interoperable data should be made clear to encourage 
clinicians‘ adoption. Physicians need to able to use the 
clinical data they collected in their records and regis-
ters for their own research, internal audit, and keep co-
ntrol of the research uses of these data by third parties. 
Many health ICT solutions exist that accommodate 
the needs of various stakeholders but lack connectivity, 
patient orientation, and most importantly fail to effec-
tively support communication and cooperation be-
tween different stakeholders in the healthcare system. 
Standards are available but many proprietary systems 
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and solutions are still not aligned with interoperability 
standards, which are limiting the possibilities for fur-
ther development. User support needs much im-
provement in terms of human interface, natural lan-
guage processing and granular reference terminologies 
which allow interoperability and at the same time 
matching diverse needs of specialty classifications. 
Current ICT use in health has shown great results in 
capturing and structuring health information, yet the 
work to link these systems to care pathways and busi-
ness processes in order to achieve continuity of care is 
still in its infancy. Strict machine processes of ICT are 
sometimes not flexible to accommodate all of the hu-
man workflow. The heterogeneous interest of various 
stakeholders makes it difficult to implement and mod-
ernize ICT fitting diverse needs to achieve interopera-
bility.  
Another limitation lies on how the ICT services are 
planned and deployed. Existing governance structures 
are not able to produce regulations and legal frame-
works which fit the current development. Using a 
pharmaceutical dominated model to prove Return on 
Investment makes it difficult for ICT in health to show 
its cost-effectiveness and consequently impede in-
vestment.  
One major problem is that standards are often cost-
ly and difficult to access which hinder the adoption by 
small-sized vendors and organizations. Standards dis-
semination needs to allow wider and easier adoption 
among all levels of stakeholder. Standards adoption is 
a continuous path as there will always be new stand-
ard developments. More effective strategies which 
include training and ongoing support of adoption have 
to be considered. Input of clinicians and patients has 
to become more strongly a part of standards develop-
ment. Cooperation and collaboration among stand-
ard bodies and vendors can save resources and avoid 
iteration and duplication when developing standards.  
The decision making power to help scaling up in-
teroperability resides in public authorities, insurers 
and the health industry, whereas clinicians and pa-
tients are in a passive position. Public authorities have 
to focus on regulations which could leverage 
unachieved efforts and unmet needs, and promote trust 
and credibility among stakeholders. The number of 
clinicians who are willing to drive the process of in-
teroperability is limited and, thus, should be supported, 
trained and coached. Scientific officers of European 
scientific associations should also be targeted to speed 
up the process of adoption of standards in clinical 
guidelines, research, decision support systems and 
registries. Ultimately, patient demand has to be edu-
cated and nurtured by patient associations. 
The audience were informed that i~HD is playing a 
growing role in the development and quality labelling 
of interoperability specifications, bringing together 
clinical and research domain experts, with patients, to 
help ensure that future standards will support patient 
care, learning health systems and clinical research.  
10. Interoperability as a driver of co-creation 
of health and wellness 
Petra Wilson told the audience that Europe is ageing 
and our dependency ratio is heading towards less than 
2:1 - that means there will be fewer than two working 
age people (15-65) for every person over 65 years old. 
The issues this raises are manifold, encompassing 
questions about working in older age, youth unem-
ployment, rise in chronic conditions, cost of care, and 
many more. Technical interoperability in health and 
wellness technology will certainly not solve all the 
problems, but it can help address a key issue: how can 
we empower and enable patients to be more actively 
engaged in evaluating their actions to promote health 
and wellness. 
The engagement of the end consumer in the devel-
opment of a good or service may be defined as having 
two aspects: co-production and co-creation. Co-pro-
duction is often described as the involvement of the 
user in the design of a product, which has arguably 
has been the case in healthcare for many years with 
the use of the controlled trial in drug development. 
The term co-creation is often used to describe the con-
tinuous engagement of the user in service use to create 
on-going value for the user and others
 [33]
. Co-creation 
sees the role of patients extending beyond being pas-
sive health care recipients, or even active participants 
in their own care, to involvement in innovation and 
value creation in health care — from being ―users and 
choosers‖ to becoming ―makers and shapers‖ of ser-
vices
[34]
.
 
Co-creation in healthcare is complex and is 
slowly evolving through the input of many disciplines 
including sociology, psychology, management science 
and many more. Here we are interested in exploring 
the role of health informatics can play in adding to the 
on-going endeavours to ensure that patients can be-
come co-creators of not only their own health, but of 
evolving healthcare systems. 
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The emergence of wearable and implanted devices 
for continuous monitoring, ambient data collection 
tools such as pedometers, social media records of 
mood and situation, geo-location devices and many 
other new technologies, offer an opportunity for the 
patient to engage directly in the co-creation of their 
own health and the development of health systems 
(Figure 7). They offer the potential to collect real-time, 
personal and contextual data to help patients and cli-
nicians understand the impact of a medication, situa-
tion, mood, exercise or other external factors on health.  
 
 
 
Figure 7. The five E‘s – characteristics of co-creation of health 
 
The key to unlocking that potential, to igniting the 
engine that will drive real change in healthcare, is the 
extent to which the data can be shared and re-used. To 
ensure that we can use the many new technologies that 
allow for better data collection in a truly co-creative 
way, we need to ensure that they can be reliably col-
lected, safely processed, shared, used and reused. 
While this a huge ask, two key components to ad-
dressing it are within our grasp: interoperability of 
health information systems and health information 
governance frameworks.   
These two components demand that SDOs must 
develop good standards and profiles, which law mak-
ers must devise new concepts of data custodianship 
and that policy makers must shape the policies which 
ensure that the standards are used and the governance 
frameworks are user-friendly. These are of course 
huge tasks, but ones that we are equipped to tackle, 
and indeed must tackle if we want to ensure that our 
health systems evolve to be co-created through the 
active engagement of patients, empowered to share 
their data so that systems can be continuously evalu-
ated to drive an evolution towards a sustainable 
healthcare system that values the promotion wellness 
rather than the rectification of harm.  
11. How to speak to politicians to engage coun-
tries in the fight for prevention of brain disorders 
Mary Baker, MBE, gave the afternoon keynote talk 
about the societal challenge of an ageing society, the 
growing challenge of multiple chronic diseases and 
the need to accelerate research into innovative treat-
ments. Drawing on her long experience working for 
professional societies and charities in neurological 
disease, Mary pointed out that brain research in Eu-
rope is a rapidly evolving field. The complexity of 
understanding brain function and brain diseases brings 
responsibilities as well as opportunities for the neuro-
science community for the benefit of society. Despite 
these major challenges and all the efforts of the scien-
tific community in Europe, we are still struggling 
against the discrepancy, still present in Europe, be-
tween the huge societal impact of brain diseases on 
the one hand, and the modest financial and time re-
sources allocated for brain research, teaching and the 
care of brain diseases on the other. There is no way to 
escape from the fact that brain disorders are a major 
public health problem in Europe and the rest of the 
world. An analysis of the health economic studies 
of brain diseases in Europe, published by the Europe-
an Brain Council in 2011, led to an estimate of 
€798 billion for the total cost of brain disease in Eu-
rope in 2010. This burden is bound to grow. Address-
ing these large costs requires intensified resea-
rch, both basic and clinical, and the creation of novel 
solutions. Future generations deserve nothing less. 
We must work with the policy makers. We must al-
so understand the policies and the active outlines pre-
sented by the various directorates of the Commission 
and work to use the aspirations of each Presidential 
term of each Country to benefit society.   
The combination of ageing populations and lower 
economic growth is leading policy makers to question 
the sustainability of European healthcare expenditure. 
At the same time as seeking to increase ‗cost-effec-
tiveness‘, however, we must also strengthen our focus 
on the outcomes our health systems deliver - for the 
patient, the economy, and society. 
Society needs to be much more committed to pro-
moting wellness and accelerating the discovery and 
testing of innovative treatments. Our ageing society is 
accumulating long-term conditions, and we need to be 
much more proactive in prevention and early detection. 
Health data are vital to improving our understanding 
of disease and the impact on the lives and wellbeing of 
Interoperable Data and a good governance Framework 
for data use will allow me - the patient – to become a 
co-creator of health and wellness 
• Engage - me in my healthcare journey. 
• Empower - me to play a key role in my health 
and wellness 
• Educate - me, my provider and the community 
• Evaluate - the learning for me, my providers, 
the system and the community 
• Evolve - the system to better meet my and its 
demands. 
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patients. Society needs to better trust the security 
measures that can nowadays be applied to protect pri-
vacy, and to recognise the balance in proportionali-
ty between safeguarding health data and putting health 
data to good use. 
Conclusion 
i~HD has been established as a European not for prof-
it body, registered in Belgium through Royal Assent. It 
is governed by its member stakeholders, public and 
private, through an elected Board and officers. It 
is being financed by a mixture of membership sub-
scriptions, and will in the future add income from fees 
from providing services such as certification and ac-
creditation, specific project grants and other income 
from education, training and expert advisory roles. 
i~HD will continue to work on the development 
of best practices to promote a trustworthy ecosystem 
for reusing health data for research, and the adoption 
of standards for high quality and interoperable health 
data. i~HD will also be working with patient associa-
tions to understand their views on societally accepta-
ble ways to scale up learning from health data, and 
how such learning can also ensure patient involvement 
and empowerment. 
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